Related Experiment Video
Updated: Aug 13, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Vivitrex (Alkermes/Cephalon)
1Faculty of Science, The Open University in the North, Eldon House, Regent Centre, Gosforth, Newcastle-upon-Tyne NE3 3PW, UK. moore11@globalnet.co.uk
Abstract:
Vivitrex, an injectable, sustained-release formulation of the opioid antagonist naltrexone, is being developed by Alkermes and Cephalon for the potential once-monthly treatment of alcoholism and opiate use disorder. Alkermes and Cephalon are currently awaiting Food and Drug Administration review of the Vivitrex new drug application, which was granted Priority Review in May 2005.
Related Concept Videos
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Therapy
Antianxiety Medications
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Drug Abuse and Addiction: Pharmacological Phenomena
Drug Dependence
